Skip to content

Acknowledgements

About This Work

This framework was developed as an independent research project (November 2025 – January 2026) investigating decision governance in regulated biopharmaceutical environments. It synthesizes publicly available regulatory guidance, academic literature, industry analysis, and professional standards to propose a structured approach to decision documentation in phase-gated drug development.

The work is released as an open-source research framework under the Apache License 2.0. While it references Syner-G BioPharma Group's contributions to regulatory science, it was created without organizational affiliation or sponsorship.

Acknowledgements

I am grateful to the regulatory agencies, academic centers, professional societies, and industry practitioners whose published work shaped the conceptual foundations of this project.

The U.S. Food and Drug Administration's January 2025 draft guidance on artificial intelligence in regulatory decision-making [10] and its seven-step credibility assessment framework [46][47][48] provided the principal regulatory scaffold for the RGDS model. Recognition of decision reconstructability challenges in FDA Form 483 observations [38] helped crystallize the core thesis: that regulatory deficiencies often stem not from scientific capability but from ambiguous decision rationale and incomplete evidence documentation. International guidance from the WHO, EMA, and ICH on AI transparency, pharmacovigilance governance, and regulatory harmonization informed the framework's positioning for global applicability.

I also acknowledge the Tufts Center for the Study of Drug Development [35], the Duke-Margolis Institute for Health Policy, MIT Sloan Executive Education, the Regulatory Affairs Professionals Society [71], FDLI [49], ISPE [14], and industry analysts at Lumanity, McKinsey, Deloitte [56][78], Analysis Group [25][77], and Certara [6][59], whose research and analyses informed the evidence base, ROI modeling, and regulatory strategy discussions throughout this work. The decision architecture draws on established frameworks including RACI/DACI [16][17], Critical Path Method [18], and portfolio management methodologies [22][79][83], as well as FDA work on explainability and interpretability [10][46][48][69] and quality management maturity [39].

I thank the contributors and maintainers of the open-source tools used to build this documentation, including MkDocs (BSD-2-Clause; © 2014 Tom Christie) and Material for MkDocs (MIT; © 2016–2026 Martin Donath). Complete license texts are available in the THIRD_PARTY_LICENSES file.

AI-Assisted Research Disclosure

In developing this project, I used AI-enabled tools—including large language models and web-based research platforms—to assist with literature discovery, evidence synthesis, schema design, drafting, and editing (November 2025 – January 2026). These tools supported organization, speed, and clarity but did not replace human judgment. I remain solely responsible for the selection, interpretation, and integration of all sources. All regulatory citations were verified against original agency documents, industry analyses were cross-checked with primary publications, technical implementations were tested against real-world use cases, and all 96 bibliography entries were confirmed for accuracy and accessibility.

AI tools were not listed as authors or co-authors, consistent with ICMJE recommendations on AI-assisted technology in scholarly work. A detailed description of research tooling, AI-assisted workflows, and validation procedures is available in the Supplementary Materials and Technical Notes.

Research Integrity

This work synthesizes publicly available research, regulatory guidance, industry analysis, and professional best practices. All direct citations reference the complete bibliography, entries [1–96], with attribution provided throughout the framework.

Where RGDS extends or reinterprets existing frameworks—for example, adapting FDA's seven-step credibility framework for decision-governance purposes—the extension is explicitly noted and the original source is cited. Financial analysis methodology and ROI modeling details are documented in Appendix A.

The goal is transparency: readers should be able to trace claims back to their sources and form their own judgments about the strength of evidence.

Disclaimer

This framework is provided for informational and educational purposes only and does not constitute regulatory, legal, medical, or professional advice. It represents independent research and analysis synthesizing publicly available information.

No Warranty. This work is provided "as-is" under the Apache License 2.0, without warranties of any kind, either express or implied, including warranties of accuracy, completeness, or fitness for a particular purpose.

Regulatory Compliance. Organizations operating in regulated industries should consult qualified regulatory affairs, legal, and compliance professionals before implementing any governance framework. Regulatory requirements vary by jurisdiction and application.

Professional Consultation. This framework is not a substitute for professional advice tailored to specific circumstances. Users are responsible for conducting their own due diligence and validation.

No Affiliation. References to regulatory agencies, organizations, companies, or products are for informational purposes only and do not imply endorsement or affiliation.

RGDS Project Repositories

This documentation references the following repositories, licensed under the Apache License 2.0:

  • RGDS Core Framework — Decision log schemas, governance covenants, and canonical examples
  • RGDS AI Governance — Governance boundaries and non-agentic AI constraints for regulated decision support

Document Version

Citation Format

All inline citations follow the format [\[N\]](bibliography.md#citeN) where N refers to the bibliography entry number. To view full citation details, visit the Bibliography page.